FDA Endocrinologic and Metabolic Drugs Advisory Committee
Executive Summary
Will review NDAs for Schering's Eulexin (flutamide) as an adjuvant treatment for metastatic prostate cancer on Feb. 25, and Alza's transdermal testosterone patch for hypogonadism on Feb. 26. Committee will meet in conference rooms D & E of FDA's Parklawn Building at 9 a.m. both days.